Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.02.17	Regeneron Announces Upcoming 2017 Investor Conference Presentations (PR Newswire)
10.02.17	Regeneron Gets Subpoena On Patient Assistance Non-profit (RTTNews)
09.02.17	Regeneron Pharmaceuticals Reports 37% Rise In Q4 Profit (RTTNews)
09.02.17	Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results (PR Newswire)
09.02.17	AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban (RTTNews)
09.02.17	Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent (RTTNews)
08.02.17	Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process (PR Newswire)
01.02.17	Regeneron And Sanofi Say Canada Approves Kevzara (RTTNews)
01.02.17	Regeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada (PR Newswire)
24.01.17	Forty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists (PR Newswire)
23.01.17	Biotech Stocks Under Scanner -- Kite Pharma, BioPharmX, OvaScience, and Regeneron Pharma (PR Newswire)
10.01.17	Amgen Issues Statement On Court Decision On Patent Litigation (RTTNews)
06.01.17	Regeneron Remains Firmly Negative After Early Decline (RTTNews)
06.01.17	OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC (RTTNews)
06.01.17	Regeneron, Sanofi To Appeal U.S. Court Rulings In Patent Litigation On Praluent (RTTNews)
04.01.17	Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management (PR Newswire)
22.12.16	Science Publication Highlights the Precision Medicine Approach of Geisinger Health System and the Regeneron Genetics Center (PR Newswire)
22.12.16	Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System (PR Newswire)
08.12.16	Technical Reports on Biotech Equities -- Aurinia Pharma, Threshold Pharma, Regeneron Pharma, and INSYS Therapeutics (PR Newswire)
08.12.16	NWBO To Leave Nasdaq, Voyager Cruises Ahead, Watch Out For REGN (RTTNews)
08.12.16	Regeneron, Sanofi: EMA Accepts Dupixent Marketing Application For Review (RTTNews)
08.12.16	Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA (PR Newswire)
18.11.16	BSTC Finds New Use For Old Drug, FHCO Gets A Boost, SUPN Put On Notice (RTTNews)
04.11.16	Regeneron Pharmaceuticals Announces 32% Increase In Q3 Profit (RTTNews)
31.10.16	BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal (RTTNews)
17.10.16	Regeneron, Teva: FDA Places Phase 2b Fasinumab Back Pain Trial On Clinical Hold (RTTNews)
13.10.16	Ocular Therapeutix Signs Strategic Collaboration With Regeneron Pharma (RTTNews)
03.10.16	DEPO Wins Patent Suit, EBS Surges On BARDA Funding, REGN's Eylea Combo Fails (RTTNews)
02.10.16	Regeneron, Sanofi: Dupixent Phase 3 Atopic Dermatitis Studies Meet Primary Goal (RTTNews)
30.09.16	Regeneron Pharma Reports Topline Results From Phase 2 CAPELLA Study (RTTNews)
29.09.16	Biotech Stocks Facing FDA Decision In October (RTTNews)
26.09.16	Regeneron, Sanofi: FDA Accepts Dupilumab BLA For Priority Review - Quick Facts (RTTNews)
20.09.16	Regeneron Pharma And Teva Pharma Reach Agreement To Commercialize Fasinumab (RTTNews)
29.08.16	Regeneron, Sanofi Report Positive Data For Praluent - Quick Facts (RTTNews)
23.08.16	BPMX Scores A Facelift, MDVN Says "I Do" To PFE, Europe Gets Its 1st HIV PrEP (RTTNews)
04.08.16	Regeneron Pharmaceuticals Reveals 24% Gain In Q2 Profit (RTTNews)
03.08.16	RIGL Awaits Key Data This Month, GeoVax Gets Funding, ADXS Jumps On Amgen Deal (RTTNews)
01.08.16	Sanofi: EMA To Review Marketing Authorisation Application For Sarilumab (RTTNews)
05.07.16	Regeneron Says Japan Approves Praluent To Treat Hypercholesterolemia (RTTNews)
07.06.16	ADMP Snubbed Again, OCUL, DNAI Skid On Trial Data, AGN Gets FDA Nod. SRPT Abuzz (RTTNews)
06.06.16	Regeneron: Dupilumab With Topical Corticosteroids Superior To Treatment With TCS (RTTNews)
31.05.16	Regeneron Presents Positive Interim Data From Phase 2 Study Of Evinacumab (RTTNews)
05.05.16	Regeneron Pharma Q1 Profit Surges (RTTNews)
05.05.16	Regeneron Pharmaceuticals Announces 13% Decline In Q1 Bottom Line (RTTNews)
02.05.16	Regeneron Reports Positive Results From Phase 2/3 Fasinumab Study - Quick Facts (RTTNews)
01.04.16	Regeneron Seeing Further Upside After Initial Jump (RTTNews)
01.04.16	Regeneron: Two Dupilumab Phase 3 Studies Meets Primary Endpoints - Quick Facts (RTTNews)
24.03.16	Regeneron, Bayer To Jointly Develop Combination Therapy For Eye Diseases (RTTNews)
24.03.16	Odyssey Hits The Mark, SPHS Awaits Data In Q2, TEVA Breathes Easy (RTTNews)
23.03.16	Regeneron, Sanofi: Praluent Study Meets Goal In LDL Apheresis Therapy Patients (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	535.80	0.90 %	K V
Sonova Hldg	306.60	0.66 %	K V
Novartis	92.26	0.36 %	K V
Roche Hldg G	252.20	0.32 %	K V
Alcon	77.82	0.26 %	K V
ABB	49.20	-0.69 %	K V
UBS Group	27.55	-0.76 %	K V
CieFinRichemont	121.35	-0.82 %	K V
Sika	226.40	-0.96 %	K V
Logitech Intl	70.64	-1.86 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus